VISTA in hematological malignancies: a review of the literature DOI Creative Commons

Yuanjia Duan,

Xiaotong Ren, Xinyu Guo

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 17, 2024

In recent years, tumor immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic effects. V-domain Ig suppressor T-cell activation (VISTA) is a new type receptor highly expressed in various tumors. It co-expressed PD-1, immunoglobulin domain, mucin domain-3 (Tim-3), immunoglobulin, immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) associated prognosis, which suggests it may be target for As no mature drugs, VISTA acute myeloid leukemia (AML), multiple myeloma (MM), hematological malignancies; however, its pathogenic mechanism should defined to better guide treatment.

Language: Английский

Multi-pathway oxidative stress amplification via controllably targeted nanomaterials for photoimmunotherapy of tumors DOI Creative Commons
Hang Li,

Yunheng Liu,

Xiaokang Zhang

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 22, 2025

Photoimmunotherapy, which combines phototherapy with immunotherapy, exhibits significantly improved therapeutic effects compared mono-treatment regimens. However, its use is associated drawbacks, such as insufficient reactive oxygen species (ROS) production and uneven photosensitizer distribution. To address these issues, we developed a controllable, targeted nanosystem that enhances oxidative stress through multiple pathways, achieving synergistic photothermal, photodynamic, immunotherapy for tumor treatment. These nanoparticles (D/I@HST NPs) accurately target overexpressed transferrin receptors (TfRs) on the surface of cells surface-modified (Tf). After endocytosis, D/I@HST NPs generate ROS under 808-nm laser irradiation, breaking ROS-responsive crosslinking agent increasing drug release utilization. Tf also carries Fe3+, reduced to Fe2+ by iron reductase in acidic microenvironment (TME). Consequently, endoperoxide bridge structure dihydroartemisinin cleaved, causing additional generation. Furthermore, released IR-780 exerts both photodynamic photothermal effects, enhancing cell death. This multi-pathway amplification effect can trigger immunogenic death tumors, promoting relevant antigens damage-associated molecular patterns, thereby dendritic maturation sensitivity immunotherapy. Mature transmit signals T cells, infiltration activation, facilitating growth inhibition suppression lung metastasis. myeloid-derived suppressor decreases after In summary, this stress-amplified effectively inhibits reverses immunosuppressive microenvironment, provides new insights into combined phototherapy.

Language: Английский

Citations

2
CD28 co-stimulation: novel insights and applications in cancer immunotherapy DOI
Michael T. Lotze, Scott H. Olejniczak, Dimitris Skokos

et al.

Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: 24(12), P. 878 - 895

Published: July 25, 2024

Language: Английский

Citations

15
VISTA-induced tumor suppression by a four amino acid intracellular motif DOI Creative Commons
Yan Zhao,

T Andoh,

Fatima Charles

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 5, 2025

Summary VISTA is a key immune checkpoint receptor under investigation for cancer immunotherapy; however, its signaling mechanisms remain unclear. Here we identify conserved four amino acid (NPGF) intracellular motif in that suppresses cell proliferation by constraining cell-intrinsic growth signaling. The NPGF binds to the adapter protein NUMB and recruits Rab11 endosomal recycling machinery. We characterize class of triple-negative breast cancers with high expression low proliferative index. In tumor cells levels, sequesters at endosomes, which interferes epidermal factor (EGFR) trafficking suppress growth. These effects do not require canonical ligands, nor functioning system. As consequence expression, EGFR remains abnormally phosphorylated cannot propagate ligand-induced Mutation domain reverts VISTA-induced suppression multiple mouse models. results define mechanism represses control malignant epithelial They also distinct residues are critical could be exploited improve immunotherapy.

Language: Английский

Citations

1
Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy DOI Creative Commons

MariaLuisa Vigano,

Lixing Wang,

Alia As’sadiq

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 5, 2025

Cannabinoids relieve pain, nausea, anorexia and anxiety, improve quality of life in several cancer patients. The immunotherapy with checkpoint inhibitors (ICIs), although very successful a subset patients, is accompanied by moderate to severe immune-related adverse events (ir-AE) that often necessitate its discontinuation. Because their role symptomatic relief, cannabinoids have been used combination immune inhibitor (ICI) immunotherapy. A few studies strongly suggest the use medicinal cannabis patients attenuates many ir-AE associated ICI increase tolerability. However, no significant beneficial effects on overall survival, progression free survival or relapses were observed; rather, some noted concurrent administration clinical benefits latter. cannabinoids' well documented immunosuppressive mediated through cannabinoid recptor-2 (CB2), we propose considering this receptor as an inhibitory per se. simultaneous neutralization CB2, treatment, may lead better outcomes receiving In regard, such cannabidiol (CBD) cannabigerol (CBG), little agonism for be therapeutic choices. Additional strategies e.g., monoacylglycerol lipase (MAGL) degrade endocannabinoids lipogenesis formation lipid bilayers cells also explored. Future should take into consideration gut microbiota, CYP450 polymorphism haplotypes, cannabinoid-drug interactions genetic somatic variations occurring receptors signaling pathways personalized cannabis-based therapies ICIs. This rational knowledge-based regimens tailored individual

Language: Английский

Citations

1
Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside DOI Creative Commons

Yiming Luo,

Ye Yuan, Shilin Liu

et al.

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

The B7-H family of immune checkpoint molecules is a crucial component the regulatory network for tumors, offering new opportunities to modulate tumor microenvironment (TME). - which includes B7-H2 (inducible T cell costimulatory ligand, ICOSL), B7-H3, B7-H4, B7-H5 (V-domain immunoglobulin suppressor activation, VISTA), B7-H6, and B7-H7 (HHLA2) known its diverse roles in regulating innate adaptive immunity. These can exhibit co-stimulatory or co-inhibitory effects on cells, influencing processes such as differentiation, effector functions, they are involved recruitment polarization various cells. This review explores structural characteristics, receptor-ligand interactions, signaling pathways associated with each member. We also discuss family's impact immunity potential therapeutic strategies.

Language: Английский

Citations

0
Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy DOI Creative Commons
Xiaofeng Ren,

Anjie Guo,

Jiahui Geng

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 24, 2025

Background The widespread use of immune checkpoint inhibitors (anti-CTLA4 or PD-1) has opened a new chapter in tumor immunotherapy by providing long-term remission for patients. Unfortunately, however, these agents are not universally available and only minority patients respond to them. Therefore, there is an urgent need develop novel therapeutic strategies targeting other co-inhibitory molecules. However, comprehensive information on the expression prognostic value molecules, including receptors their ligands, different cancers yet available. Methods We investigated expression, correlation, molecules cancer types based TCGA, UCSC Xena, TIMER, CellMiner datasets. also examined associations between extent cell infiltration. Besides, we conducted more in-depth study VISTA. Result results differential analysis, correlation drug sensitivity analysis suggest that CTLA4, PD-1, TIGIT, LAG3, TIM3, NRP1, VISTA, CD80, CD86, PD-L1, PD-L2, PVR, PVRL2, FGL1, LGALS9, HMGB1, SEMA4A, VEGFA associated with prognosis believe they hopefully serve as biomarkers certain cancers. In addition, our indicates VISTA plays complex role its related TMB, MSI, stemness, DNA/RNA methylation, sensitivity. Conclusions These have potential targets broad spectrum cancers, given strong key clinical metrics. Furthermore, indicate may represent promising target therapy.

Language: Английский

Citations

0
Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity DOI Creative Commons

Taylor J. Moon,

Hieu Minh Ta,

Anubhuti Bhalotia

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2024, Volume and Issue: 12(8), P. e008977 - e008977

Published: Aug. 1, 2024

Immune checkpoint protein V-domain immunoglobulin suppressor of T cell activation (VISTA) controls antitumor immunity and is a valuable target for cancer immunotherapy. Previous mechanistic studies have indicated that VISTA impairs the toll-like receptor (TLR)-mediated myeloid antigen-presenting cells, promoting expansion myeloid-derived suppressing tumor-reactive cytotoxic function.

Language: Английский

Citations

2
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy DOI Creative Commons

Zhouchi Yao,

Yayun Zeng,

Cheng Liu

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Sept. 28, 2024

Language: Английский

Citations

2
Small Molecule Inhibitors Targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for Cancer Immunotherapy (2020-2024) DOI
Binbin Cheng,

Jiaoli Lv,

Yao Xiao

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 283, P. 117141 - 117141

Published: Dec. 5, 2024

Language: Английский

Citations

2
Epigenetic control of commensal induced Th2 Responses and Intestinal immunopathology DOI Open Access
Kishan Sangani, Morgan E. Parker, Hope D. Anderson

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 30, 2024

Understanding the initiation of T-helper (Th)-2 immunity is crucial for addressing allergic diseases that have been linked to commensal microbiota. However, Th2 responses are notably absent from known host-microbiota intestinal immune circuits. Notably, protist

Language: Английский

Citations

1